ArticleFrontiers in oncology2026
A novel explainable AI for revealing determinants of cancer drug response through integrative multi-omics analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer drug response rates differ across patients and cell lines; however, many current computational prediction models still function as uninterpretable black boxes, offering limited insight into why a given treatment works well for some patients or cell lines but poorly for others. Methods: Here, we introduce an interpretable cancer drug response prediction framework that leverages multi-omics data from the Genomics of Drug Sensitivity in Cancer 2 (GDSC2) resource, including genomics, transcriptomics, and proteomics, where available, together with explicit chemical drug descriptors derived from SMILES and InChI representations. We use a Modified Neighbor-Joining Algorithm (MNJA) to generate topology-aware gene-sequence trees. Combined multi-omics and drug features are summarized into high-level deep descriptors via a decimal-scaled GoogLeNet (DS-GoogLeNet), together with lightweight handcrafted features. A Smoluchowski Kookaburra Optimization Algorithm (SKOA) then selects informative multimodal features, which are used to classify the sensitivity or resistance of each cell line-drug pair with an explainable Aranda Graph Attention Network (EA-GAT). Results: By analyzing model behavior using SHAP-based feature attributions and subsequently subjecting SHAP-ranked genes to pathway enrichment analysis, we highlight the recurrent involvement of the PI3K/AKT/mTOR pathway and related downstream signaling cascades in drug response. Under leakage-safe stratified 10-fold cross-validation on 2614 GDSC2 cell line-drug pairs, the framework attains an accuracy of 95.87% and an F1-score of 95.87%, with an area under the receiver operating characteristic curve (AUROC) of 0.957 and an area under the precision-recall curve (AUPRC) of 0.946. Discussion: Overall, the framework appears to predict drug response accurately while also supporting biologically meaningful interpretation, making it a useful computational tool for hypothesis generation and biomarker-focused investigation in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.